Cantor Fitzgerald Reiterates Overweight on Trulieve Cannabis, Maintains $15 Price Target
Cantor Fitzgerald analyst Gabie Ingoglia reiterates Trulieve Cannabis (NYSE:TRLV) with a Overweight and maintains $15 price target.
Read original at benzingaStocks · News reference
Trulieve Cannabis Q2 Adj. EPS $0.11 Beats $0.06 Estimate, Sales $271.000M Beat $268.494M Estimate
Trulieve Cannabis (NYSE:TRLV) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.06 by 83.33 percent. This is a 375 percent increase over losses of $(0.04) per share from the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 1:04 PM
- Checked
- Aug 7, 2026, 1:04 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Trulieve Cannabis Corp. (TRLV)
Filed: 2026-08-07 AccNo: 0001754195-26-000067 Size: 6 MB Item 2.01: Completion of Acquisition or Disposition of Assets Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarCantor Fitzgerald Initiates Coverage On Trulieve Cannabis with Overweight Rating, Announces Price Target of $15
Cantor Fitzgerald analyst Gabie Ingoglia initiates coverage on Trulieve Cannabis (NYSE:TRLV) with a Overweight rating and announces Price Target of $15.
Read original at benzinga